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SUMMARY
Ten antisera were produced in rabbits by two or three intravenous injections of inactivated
whole influenza type A virions. All contained haemagglutination-inhibition (HI) antibody
directed predominantly to an epitope in antigenic site B and, in addition, various amounts of
antibodies to an epitope in site A and in site D. The ability of untreated antisera to select
neutralization escape mutants was investigated by incubating virus possessing the homologous
haemagglutinin with antiserum adjusted to contain anti-B epitope HI titres of 100, 1000 and
10000 HIU}ml. Virus-antiserum mixtures were inoculated into embryonated hen’s eggs, and
progeny virus examined without further selection. Forty percent of the antisera at a titre of
1000 HIU}ml selected neutralizing antibody escape mutants as defined by their lack of
reactivity to Mab HC10 (site B), and unchanged reactivity to other Mabs to site A and site D
epitopes. All escape mutant-selecting antisera had a ratio of anti-site B (HC10)-epitope
antibody:other antibodies of & 2±0:1. The antiserum with the highest ratio (7±4:1) selected
escape mutants in all eggs tested in four different experiments. No antiserum used at a titre of
10000 HIU}ml allowed multiplication of any virus. All antisera used at a titre of 100 HIU}ml
permitted virus growth, but this was wild-type (wt) virus. We conclude that a predominant
epitope-specific antibody response, a titre of & 1000 HIU}ml, and a low absolute titre of other
antibodies (% 500 HIU}ml) are three requirements for the selection of escape mutants. None of
the antisera in this study could have selected escape mutants without an appropriate dilution
factor, so the occurrence of an escape mutant-selecting antiserum in nature is likely to be a
rare event.
INTRODUCTION
Type A and type B influenza viruses are a major cause
of human respiratory disease, and of mortality in the
elderly and those with predisposing clinical conditions
such as chronic diseases of the heart, lungs and
kidneys [1]. Influenza viruses undergo continuous
antigenic change of their surface haemagglutinin (HA)
and neuraminidase (NA) proteins, so that both
natural and vaccine-acquired immunity rapidly be-
* Present address : 2 Kidds Way, Stonington, CT 06378-2311,
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 Author for correspondence.
come redundant unless vaccination is repeated on an
annual basis with the current virus strains. The
inactivated vaccine gives 60–90% protection against
the homologous strain [2]. Type A and B viruses
undergo antigenic changes through the phenomenon
of antigenic drift, and type A viruses by antigenic shift
[3]. However, most influenza is caused by epidemics
resulting from antigenic drift in which the viral
surface antigens undergo progressive antigenic
changes, so that immunity gained from infection is no
longer effective after about 4 years. Both the HA and
the NA undergo antigenic drift, but changes in the
former are clinically the most significant. Such viruses
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have at least 4 amino acid substitutions in 2 separate
antigenic sites of the HA [4].
Current theory holds that antigenic drift is driven
by antibody, and that this can be modelled by
neutralizing antibody escape mutants in the lab-
oratory. However, there is a problem with this logic
because escape mutants only arise in the presence of a
single monoclonal antibody (Mab). When two or
more Mabs to discrete epitopes are present in
equivalent amounts, no escape mutants are selected.
This happens because the frequency of one amino acid
substitution is about 10−&, and of two is 10−"!, and
variants are not seen to arise at this rate. Thus one
would not expect a polyclonal antiserum to be able to
select escape}drift mutants. It has been known for
nearly half a century that escape mutants of different
viruses can be isolated in the laboratory using immune
serum. However, these experiments have all required
non-natural conditions, such as highly selected
fractions of influenza antiserum [5–8], or low concen-
trations of foot-and-mouth disease virus [9, 10], or
HIV antiserum [11, 12] and usually many sequential
passages in the presence of the selecting antibody. In
vivo escape mutants have arisen when vaccination of
cattle with foot-and-mouth disease virus [13] or man
with hepatitis B virus [14, 15] or during persistent
infection of man or non-human primates by HIV-1
[16–19], resulted in sub-protective immunity. In
addition, our recent work has shown that some of the
antisera (12%) from mice immunized 2 or 3 times
subcutaneously with inactivated whole influenza A
virus were able to select escape mutants to an epitope
in antigenic site A, and hence appeared to have an
epitope-biased HA-specific secondary antibody re-
sponse. Analysis of antisera from rabbits immunized
with the same virus in a variety of routes, formulations
and up to three doses showed that the HA epitope
specificity in all of many antisera representing the
secondary antiserum response of 12 rabbits studied
was also biased to a single epitope, but in antigenic
site B. The response was not genetically determined
because mice of three different haplotypes and rabbits
of three different breeds all behaved in the same way
[20–22]. The natural situation can be modelled with
Mabs, and escape mutants were selected without
hindrance provided one Mab predominated, and the
other 2 or 3 Mabs in the mixture constituted a small
proportion of the total titre [20].
Here we report that nearly half the rabbit antisera
that were biased to an epitope in antigenic site B were
able to select antibody escape mutants. This ability
depended on both the ratio of these site B epitope-
specific antibodies to other antibodies present, and on
the absolute titres of all these antibodies.
MATERIALS AND METHODS
Viruses
Influenza A}fowl plague virus}Rostock}34 (A}FPV}
R: H7N1) and A}fowl plague virus}Dutch}27
(A}FPV}D: H7N7) were plaque-purified and grown
in the allantoic cavity of 10-day-old embryonated
hen’s eggs for 20 h at 35 °C. These viruses have
closely related haemagglutinins and unrelated neura-
minidases [21]. Virus was purified by differential
centrifugation [20]. Infectivity was measured by
plaque assay in monolayers of MDCK cells under
an agar overlay medium. Haemagglutination and
haemagglutination-inhibition (HI) assays used doub-
ling dilutions of virus in 100 ll PBS and 2% chicken
red blood cells. A 50% end-point was interpolated
between complete and no agglutination. HI titres were
determined with doubling dilutions of antibody and
four haemagglutinating units (HAU) of virus, again
by interpolation.
Preparation of antisera to type A influenza virus
Young adult New Zealand White, English Half-Lop
and Chinchilla F1 rabbits were obtained from a
number of different suppliers. These were immunized
by inoculation of 5¬10% HAU purified A}FPV}D
virus into a peripheral ear vein, except for rabbit 3A1
which received A}FPV}R in the same way (Table 1
and [21, 22] for more details). Rabbits 191, 192 and
2A6 received virus inactivated with 0±1% b-
propiolactone (Sigma), although A}FPV does not
multiply in rabbits. All rabbits received a priming
injection plus a variable number of booster (B)
injections as indicated in Table 1. Serum was obtained
from venous blood from the ear, and was stored
without preservative at ®20 °C. All animal experi-
ments followed the guidelines laid down by the UK
Coordinating Committee for Cancer Research.
Assay of HA-epitope specificities present in antisera
The HA epitope specificity of antisera was assayed
using neutralizing antibody double escape mutants
and HI assays [20]. Briefly, double escape mutants
were prepared as above from wt FPV}R by sequential
selection with 2 of 3 FPV}R neutralizing Mabs (HC2,
HC10 and HC61). These are directed to epitopes
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Table 1. Summary of immunization schedules and titration of the epitope-
specific HI titres present in rabbit antisera*
Antiserum
1}HI titre of antiserum using the
escape mutants
Rabbit designation A­B®D® A®B­D® A®B®D­
Chinchilla F1 45 B­6 9000 100000 4500
New Zealand White 191 BB­7 13000 100000 9000
New Zealand White 6 B­6 18000 71000 4500
New Zealand White 192 BB­14 4500 25000 4500
New Zealand White 192 BB­7 4500 18000 4500
New Zealand White 192 B­21 2000 4500 1000
Half-Lop 40 BB­8 50000 141000 50000
New Zealand White 3A1 BB­7 4500 9000 2000
Half-Lop 3B4 BB­5 2000 4000 1000
Half-Lop 2A6 B­21 1000 3000 2000
* HIU}ml; see text for an explanation of the rationale of using double
neutralization escape mutants for this assay.
 All rabbits were immunized intravenously ; the antiserum designation 45 B­6 is
shorthand for : rabbit 45 given a primary inoculation andone booster (B) inoculation,
and bled from an ear vein at 6 days after the boost.
which are assumed to correspond with antigenic sites
A, B or D respectively of the H3 haemagglutinin [23,
24]. In our short-hand nomenclature these are referred
to by the site which has not been mutated as a result
of Mab selection: e.g. ‘A+ ’ refers to the escape mutant
A+B−D−, which is mutated in the HC10 epitope of site
B and the HC61 epitope of site D as a result of
selection with the respective Mabs, but not at the HC2
epitope of site A. In this way we also produced ‘B+ ’
(A−B+D−) and ‘D+ ’ (A−B−D+) double escape mutants.
The mutated sites no longer react in HI or
neutralization assays with the cognate Mab.
RESULTS
Selection of escape mutants with influenza virus-
specific antisera
The HI antibody titres determined with the double
escape mutants, are shown in Table 1. All had a
response biased to the epitope in antigenic site B that
is defined by Mab HC10, but individual antisera
varied in titre by up to 33-fold. In addition antisera
contained different amounts and different titres to
epitopes in sites A and D, but no substantial titres to
other epitopes [21, 22; data not shown]. In order to
test their ability to select escape mutants, antisera
were diluted to contain final anti-B epitope HI titres
of 100, 1000 and 10000 HIU}ml. Mixtures of A}FPV}
R virus (final concentration 10 HAU}ml or about
10' pfu}ml) and antiserum were injected (100 ll) into
the allantoic cavity of embryonated hen’s eggs and
progeny virus examined without further selection.
Eighty percent (8}10) of the antisera at a titre of
1000 HIU}ml allowed growth of virus. This was
examined by HI with Mabs HC2 (site A), HC10 (site
B) and HC61 (site D). According to these tests, 50%
(4}8) antisera selected virus that had a & 12-fold
reduction in reactivity with Mab HC10 (Table 2),
while reactivity with Mabs HC2 (site A) and HC61
(site D) was unchanged (data not shown). However,
apart from antiserum WR45, these antisera did not
select escape mutants in every egg inoculated, showing
that the conditions bordered on the edge of selection.
Properties of antisera that select escape mutants
All the antisera that selected escape mutants had a
ratio of anti-site B epitope antibody:the sum of
antibodies to the other epitopes of & 2±0 (Table 2).
WR45 B­6, the antiserum with the highest ratio
(7±4), selected escape mutants in every egg tested in
four different experiments (data not shown). Within
the limits of the available data, the emergence of
escape mutants appeared to be proportional to the
ratio of antibodies to the site B epitope:the sum of
antibodies to the other epitopes. Below a ratio of two,
no escape mutants were detected. Preliminary
sequencing of the HA gene of an escape mutant
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Table 2. Ability of antisera to select escape mutants
Ratio anti-B:
anti-A­anti-D
HI titres
Anti-B titre (HIU}ml) used to
select escape mutants
Antiserum in antiserum* 10000 1000 100
45 B­6 7±4 0}3 na 3}3 3/3 3}3 0}3
191 BB­7 4±6 0}3 na 4}4 1/4 3}3 0}3
6 B­6 3±2 0}4 na 1}4 1/4 4}4 0}4
192 BB­14 2±8 nd nd 0}5 na 4}4 0}4
192 BB­7 2±0 0}3 na 3}3 2/3 3}3 0}3
192 B­21 1±5 nd nd 4}4 0}4 4}4 0}4
40 BB­8 1±4 0}4 na 4}4 0}4 4}4 0}4
3A1 BB­7 1±4 nd nd 2}4 0}2 4}4 0}4
3B4 BB­5 1±3 nd nd 3}3 0}3 3}3 0}3
2A6 B­21 1±0 nd nd 0}4 na nd nd
* Epitope-specific antibody; data from Table 1.
 First column: number of A}FPV}R virus-positive eggs}number of eggs
inoculated.
 Second column: number of eggs yielding escape mutants}number of virus-
positive eggs; escape mutants are in bold type. Escape mutants are defined by & 12-
fold reduced reactivity with Mab HC10 (site B), and unchanged reactivity to Mabs
HC2 (site A) and HC61 (site D).
selected by antiserum WR45 B­6 revealed an inferred
single amino acid substitution at amino acid 161 in
antigenic site B (data not shown), as was found in
escape mutants to Mab HC10 [23], and confirmed the
immunological data that this antiserum was indeed
selecting conventional neutralizing antibody escape
mutants in site B. When antisera were used at a titre
of 10000 HIU}ml, no virus multiplication was
detected, showing that both wt and potential escape
mutants were neutralized. This was presumably
because there were sufficient antibodies present to
unchanged epitopes to neutralize the escape mutants.
All antisera used at a titre of 100 HIU}ml permitted
virus growth, but this was wt virus, suggesting that
there was insufficient antibody present to neutralize wt
virus (Table 2).
DISCUSSION
Data reported here show that nearly half the antisera
raised against whole inactivated type A influenza virus
are sufficiently biased in their antibody-specificity
profile to be able to select escape mutants with a
facility comparable to that of a Mab. However this
depended on three factors : (i) that HA-specific
antibodies were biased to one epitope, (ii) that
antibody to the predominant epitope had a titre of &
1000 HIU}ml, and (iii) that other antibodies present
did not exceed a combined titre of 500 HIU}ml. Thus
in nature, none of the escape mutant selecting antisera
above would have selected escape mutants, since all
required dilution to achieve the correct balance of
antibodies.
There is currently no explanation for the immune
system of rabbits not responding with antibody to the
many epitopes of the HA that do not react with Mabs
HC2, HC10 and HC61, especially as the animals are
outbred and of three different strains. None of the
epitopes of FPV is blocked by carbohydrate [25], and
there was no difference in the glycosylation sites in the
strain used in this study (S. Dimes, personal com-
munication). However, our data in mice [20] and
those of others on antibody specificity [26–28] and V
gene usage [29] show that a narrow HA-specific
antibody response can occur. The antiserum response
of human hosts to infection with H3 virus to influenza
virus HA can also be biased, and this is particularly so
in children aged ! 5 years [30–33]. Wang and
colleagues [33], using a competitive binding assay and
ELISA which examined three epitopes of the H3 HA,
found a relatively restricted response in adult human
sera taken between 1969 and 1971 but not in sera
taken in 1978. However, no functional assay to test
the ability of these sera to drive antigenic variation
was carried out, and the restriction in the HA antibody
response found by all these workers was regarded as
marginal.
Data reported here demonstrate that the previously
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observed epitope-biased antibody response can be
significant biologically in the selection of antibody
escape mutants in vitro. However, it remains to be
seen if this situation extrapolates to antibodies
resulting from infection in man. If it does, we have for
the first time a mechanism to explain antigenic drift
which is consistent with laboratory data on antibody
escape mutants, i.e. antigenic drift arises through an
epitope-biased antibody response. It is not known if
escape mutants arise during primary infection,
although data from our longitudinal study of rabbits
which show a lack of epitope bias in the early immune
response suggests this might not be the case [22].
Alternatively, escape mutants could arise during a
second infection, if a sterilizing immunity had not
been generated. For escape}drift mutants to arise in
nature, it is likely that the mucosal antibody response
would have to be biased.
If the human antibody response is biased, it seems
unlikely that the human population as a whole will be
biased to the same single epitope, as significant
natural drift variants usually have at least four amino
acid substitutions in two different antigenic sites [4].
Thus we would predict that there are at least four
different human genetic groupings each of which will
have an antibody response biased to a different
epitope. Thus when an escape mutant from a person
belonging to one genetic group is transmitted to a
person of another genetic group, it will become a
double escape mutant, and so on until enough amino
acid changes have occurred to form a clinically
significant drift variant. If human beings do make an
epitope-restricted response, we now understand how
to prevent antigenic drift arising, as this only occurs
when there is a functionally monoclonal antibody
response to the HA. What is needed is a vaccine that
can stimulate neutralizing antibodies to two or three
discrete epitopes, since under these conditions no
escape mutants arise [20]. However, there are no data
on the epitope specificity of HA antibody stimulated
by current human influenza vaccines either in ex-
perimental animals or man. Finally the quantitative
requirements of the antibody specificities of the
antiserum that gives rise to escape mutants (bias to
one epitope; a titre of & 1000 HIU}ml; and low
absolute titre to other epitopes) suggest that only rare
individuals can give rise to drift variants. A narrow
HA-specific neutralizing antibody response is most
likely in people who have only experienced one
infection with type A influenza virus, and most of
these are children.
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